1. Best SR, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, Liu T, Berger A, and Danilov AV. 2019. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. Blood Advances. In press.

2. Best SR, Liu T, Bruss N, Kittai A, Berger A, and Danilov AV. 2019. Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells. Leukemia & Lymphoma (invited manuscript). In press.

3. Gordon M, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D, Danilov AV. 2018. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 124(15): 3192-3200.

4. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz S, Savage S, Long N, Reister-Shulz A, Traer E, Abel M, ….., Danilov AV, ….., Druker BD. 2018. Functional genomic landscape of acute myeloid leukemia. Nature. doi: 10.1038/s41586-018-0623-z

5. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB. 2018. Deferred treatment is a safe and viable option for select patients with mantle cell lymphoma. Leukemia & Lymphoma. Jun 18: 1-9.

6. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB. 2018. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 124 (11): 2306-2315.

7. Edwards D, Sweeney T, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SS and Loriaux MM. 2018. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 15; 9(37): 24576-24589.

8. Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, Loriaux MM, Spurgeon SE, Danilova OV and Danilov AV. 2017. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in CLL. Haematologica. 102 (11): 1890-1900.

9. Gay ND, Kozin E, Okada CY, Danilov AV, and Spurgeon SE. 2017. Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. Leukemia & Lymphoma. Dec 18: 1-3.

10. Paiva C, Godbersen JC, Rowland T, Danes C, Berger A, and Danilov AV. 2017. Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis. Oncotarget. 8(13):21128-21139.

11. Skopeja S, Jones JD, Hamilton J, Danilov AV and Rigby WFC. 2017. Differential effector function of obinutuzumab (GA101) and rituximab on normal and CLL B cells. Journal of Immunology. 199 (4): 1275-1282.

12. Danilov AV, Li H, Press OW, Shapira I, Swinnen LJ, Noy A, Reid E, Smith SM and Friedberg JW. 2017. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 phase 2 trial. Leukemia & Lymphoma. 58(2): 461-465.

13. Agarwal A, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD and Wong SL. 2017. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a Bcl-2 inhibitor, in patients with non-Hodgkin lymphoma. British Journal of Clinical Pharmacology. 83(4): 846-854.

14. Danilov AV, Lewis LD, Lansigan F, Jones SY, Roudaia L, Highhouse B, Beaulieu BB and Brown JR. 2017. A Phase I dose-ranging study of Bendamustine and Rituximab (BR) in chronic lymphocytic leukemia (CLL) patients with comorbidities. British Journal of Haematology. 178 (5): 820-823.